2 Materials and methods 2.1 Study design This study was a multi-center, prospective, double-blind, randomized clinical trial aimed to assess the absorption rate and hence bioavailibility of an innovative oral Sucrosomial B12 (Sidevit B12 developed by Pharmanutra S.p.A, Pisa, Italy) in enhancing circulatory B12 levels in healthy deficient adults, compared to various conventional oral B12 supplement formulations, selected randomly from local pharmacies at each participating center
Research from Revolution Health & Wellness confirms that telogen effluvium is fully reversible once the underlying stressor resolves and nutrients are restored
Brain-gut and appetite regulating hormones in the control of gastric secretion and mucosal protection
Absorption and Availability A B12 deficiency can result from a lack of intrinsic factor, a substance needed to absorb B12
Evaluate the change in body weight 16 weeks after initiating SAXENDA and discontinue SAXENDA if the patient has not lost at least 4% of baseline body weight, since it is unlikely that the patient will achieve and sustain clinically meaningful weight loss with continued treatment
Therefore, considering cardiorenal protective effects, no interaction was observed between baseline SGLT2i use and efpeglenatide
